Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout
Missoula, MT – March 5, 2026 – Inimmune Corporation, a clinical-stage biotechnology company developing next-generation immunotherapies, today announced the appointments of Ferdinand Massari, M.D., as Chief Medical Officer (CMO), and Ryan McMillian as Head of Financial Strategy. The appointments strengthen the leadership team as Inimmune advances its lead allergic rhinitis program, INI-2004, toward key milestones […]
